The landscape of cell and gene therapies (CGTs) is undergoing a remarkable transformation expanding beyond oncology into the treatment of autoimmune diseases. In this expert-led session, we explored how the success of CAR-T therapies in hematologic malignancies is paving the way for broader applications in autoimmune conditions. The discussion also covered advancements in immunomodulatory techniques such as regulatory T cells (Tregs) and gene editing technologies like CRISPR, which are helping redefine therapeutic possibilities for patients with autoimmune diseases.
With over 80 recognized autoimmune conditions affecting millions globally and current treatments focused largely on symptom management—CGTs represent a promising frontier for restoring immune tolerance and achieving long-term remission. But challenges remain, from the complexity of autoimmune pathophysiology to the practical hurdles of scalability, safety, and cost.
What You’ll Learn in the Webinar:
- The drivers behind the expansion of CGTs from oncology into autoimmune indications
- Innovations in cellular engineering and immunomodulation
- Case studies illustrating early clinical success in autoimmune CGT trials
- Regulatory, clinical, and commercial considerations for living therapies
- The importance of patient engagement and education for future adoption
Download the Webinar Now
Don’t miss this opportunity to hear from leaders in regenerative medicine and immunotherapy. Download the full webinar today and stay informed on the future of CGTs in autoimmune disease treatment.
About the Presenters
Desmond Cabrera — Vice President, Global Head, Cell and Gene Therapy
Desmond Cabrera is a seasoned global operations leader with extensive experience in biotechnology and pharmaceuticals. He specializes in cell and gene therapy and has led clinical trials across multiple therapeutic areas. As VP, Head of Global Operations for a mid-sized global CRO, Desmond oversees global project management teams, financial planning, and milestone delivery. His expertise in multinational team leadership, process optimization, and strategic partnerships consistently drives operational excellence and customer satisfaction. Desmond’s track record in advancing clinical development and executing high-stakes negotiations has been instrumental in achieving corporate goals and ensuring long-term success.
Dr. Danielly Vicente, Associate Medical Director, Oncology/Hematology
Dr. Danielly Vicente is a physician-scientist with over 14 years of experience in hematology and oncology. As Associate Medical Director at Allucent, Danielly oversees medical monitoring for clinical studies, provides protocol guidance, and supports safety and data review. Her career spans both clinical and industry settings. She has managed and treated patients with a wide range of hematological and oncological diseases in private practice and has held key roles in the pharmaceutical industry. Her expertise encompasses the diagnosis and treatment of complex blood disorders, hematopoietic stem cell transplantation, and the development of clinical protocols for oncology and hematology.
Stephanie Stempf — Project Director, Global Project Leadership, Clinical Project Management
Stephanie, a Project Director specializing in Cell and Gene Therapy at Allucent, has over 15 years of clinical research experience. She oversees clinical trials, ensuring client satisfaction, timelines, and budgets while managing technical and operational aspects. Beginning in oncology at the site level, she advanced to clinical trial lead and has worked in project management since 2012. With expertise in 75+ studies across Phases I-III, oncology, immuno-oncology, and advanced therapies, she has extensive PK/PD and tumor tissue collection experience. Previously, she was a Program Manager at Tempus Labs. Stephanie holds a Microbiology degree from Michigan State University.
To view the gated content, please fill out the form below.
Share This
